Stage I Clear Cell and Serous Uterine Carcinoma: What Is the Right Adjuvant Therapy?
This single-center study aimed to retrospectively evaluate the survival outcomes of patients with FIGO stage I clear cell and serous uterine carcinoma according to the type of adjuvant treatment received. The data were collected between 2003 and 2020 and only patients with stage I clear cell or sero...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/30/1/90 |
| _version_ | 1827626952281817088 |
|---|---|
| author | Manon Lefebvre Mathilde Duchatelet Houssein El Hajj Antoine De Courrèges Jennifer Wallet Charlotte Bellier Florence Le Tinier Marie Cécile Le Deley Carlos Martinez Gomez Eric Leblanc Fabrice Narducci Delphine Hudry |
| author_facet | Manon Lefebvre Mathilde Duchatelet Houssein El Hajj Antoine De Courrèges Jennifer Wallet Charlotte Bellier Florence Le Tinier Marie Cécile Le Deley Carlos Martinez Gomez Eric Leblanc Fabrice Narducci Delphine Hudry |
| author_sort | Manon Lefebvre |
| collection | DOAJ |
| description | This single-center study aimed to retrospectively evaluate the survival outcomes of patients with FIGO stage I clear cell and serous uterine carcinoma according to the type of adjuvant treatment received. The data were collected between 2003 and 2020 and only patients with stage I clear cell or serous uterine carcinoma treated with primary surgery were included. These were classified into three groups: No treatment or brachytherapy only (G1), radiotherapy +/− brachytherapy (G2), chemotherapy +/− radiotherapy +/− brachytherapy (G3). In total, we included 52 patients: 18 patients in G1, 16 in G2, and 18 in G3. Patients in the G3 group presented with poorer prognostic factors: 83.3% had serous histology, 27.8% LVSI, and 27.8% were FIGO stage IB. Patients treated with adjuvant radiotherapy showed an improved 5-year overall survival (OS) (<i>p</i> = 0.02) and a trend towards an enhanced 5-year progression-free survival (PFS) (<i>p</i> = 0.056). In contrast, OS (<i>p</i> = 0.97) and PFS (<i>p</i> = 0.84) in the chemotherapy group with poorer prognostic factors, were similar with increased toxicity (83.3%). Radiotherapy is associated with improved 5-year OS and tends to improve 5-year PFS in women with stage I clear cell and serous uterine carcinoma. Additional chemotherapy should be cautiously considered in serous carcinoma cases presenting poor histological prognostic factors. |
| first_indexed | 2024-03-09T13:04:49Z |
| format | Article |
| id | doaj.art-79d45539efba4f308d7367b88761dcaa |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-09T13:04:49Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-79d45539efba4f308d7367b88761dcaa2023-11-30T21:50:07ZengMDPI AGCurrent Oncology1198-00521718-77292023-01-013011174118510.3390/curroncol30010090Stage I Clear Cell and Serous Uterine Carcinoma: What Is the Right Adjuvant Therapy?Manon Lefebvre0Mathilde Duchatelet1Houssein El Hajj2Antoine De Courrèges3Jennifer Wallet4Charlotte Bellier5Florence Le Tinier6Marie Cécile Le Deley7Carlos Martinez Gomez8Eric Leblanc9Fabrice Narducci10Delphine Hudry11Department of Gynecologic Oncology, Centre Oscar Lambret, 59000 Lille, FranceDepartment of Gynecologic Oncology, Centre Oscar Lambret, 59000 Lille, FranceDepartment of Gynecologic Oncology, Centre Oscar Lambret, 59000 Lille, FranceMethodology and Biostatistics Department, Oscar Lambret Comprehensive Cancer Center, 59020 Lille, FranceMethodology and Biostatistics Department, Oscar Lambret Comprehensive Cancer Center, 59020 Lille, FranceDepartment of Medical Oncology, Centre Oscar Lambret, 59000 Lille, FranceAcademic Department of Radiation Oncology, Oscar Lambret Comprehensive Cancer Center, 59020 Lille, FranceMethodology and Biostatistics Department, Oscar Lambret Comprehensive Cancer Center, 59020 Lille, FranceDepartment of Gynecologic Oncology, Centre Oscar Lambret, 59000 Lille, FranceDepartment of Gynecologic Oncology, Centre Oscar Lambret, 59000 Lille, FranceDepartment of Gynecologic Oncology, Centre Oscar Lambret, 59000 Lille, FranceDepartment of Gynecologic Oncology, Centre Oscar Lambret, 59000 Lille, FranceThis single-center study aimed to retrospectively evaluate the survival outcomes of patients with FIGO stage I clear cell and serous uterine carcinoma according to the type of adjuvant treatment received. The data were collected between 2003 and 2020 and only patients with stage I clear cell or serous uterine carcinoma treated with primary surgery were included. These were classified into three groups: No treatment or brachytherapy only (G1), radiotherapy +/− brachytherapy (G2), chemotherapy +/− radiotherapy +/− brachytherapy (G3). In total, we included 52 patients: 18 patients in G1, 16 in G2, and 18 in G3. Patients in the G3 group presented with poorer prognostic factors: 83.3% had serous histology, 27.8% LVSI, and 27.8% were FIGO stage IB. Patients treated with adjuvant radiotherapy showed an improved 5-year overall survival (OS) (<i>p</i> = 0.02) and a trend towards an enhanced 5-year progression-free survival (PFS) (<i>p</i> = 0.056). In contrast, OS (<i>p</i> = 0.97) and PFS (<i>p</i> = 0.84) in the chemotherapy group with poorer prognostic factors, were similar with increased toxicity (83.3%). Radiotherapy is associated with improved 5-year OS and tends to improve 5-year PFS in women with stage I clear cell and serous uterine carcinoma. Additional chemotherapy should be cautiously considered in serous carcinoma cases presenting poor histological prognostic factors.https://www.mdpi.com/1718-7729/30/1/90clear cell uterine carcinomaserous uterine carcinomastage Isurvivaltoxicities |
| spellingShingle | Manon Lefebvre Mathilde Duchatelet Houssein El Hajj Antoine De Courrèges Jennifer Wallet Charlotte Bellier Florence Le Tinier Marie Cécile Le Deley Carlos Martinez Gomez Eric Leblanc Fabrice Narducci Delphine Hudry Stage I Clear Cell and Serous Uterine Carcinoma: What Is the Right Adjuvant Therapy? Current Oncology clear cell uterine carcinoma serous uterine carcinoma stage I survival toxicities |
| title | Stage I Clear Cell and Serous Uterine Carcinoma: What Is the Right Adjuvant Therapy? |
| title_full | Stage I Clear Cell and Serous Uterine Carcinoma: What Is the Right Adjuvant Therapy? |
| title_fullStr | Stage I Clear Cell and Serous Uterine Carcinoma: What Is the Right Adjuvant Therapy? |
| title_full_unstemmed | Stage I Clear Cell and Serous Uterine Carcinoma: What Is the Right Adjuvant Therapy? |
| title_short | Stage I Clear Cell and Serous Uterine Carcinoma: What Is the Right Adjuvant Therapy? |
| title_sort | stage i clear cell and serous uterine carcinoma what is the right adjuvant therapy |
| topic | clear cell uterine carcinoma serous uterine carcinoma stage I survival toxicities |
| url | https://www.mdpi.com/1718-7729/30/1/90 |
| work_keys_str_mv | AT manonlefebvre stageiclearcellandserousuterinecarcinomawhatistherightadjuvanttherapy AT mathildeduchatelet stageiclearcellandserousuterinecarcinomawhatistherightadjuvanttherapy AT housseinelhajj stageiclearcellandserousuterinecarcinomawhatistherightadjuvanttherapy AT antoinedecourreges stageiclearcellandserousuterinecarcinomawhatistherightadjuvanttherapy AT jenniferwallet stageiclearcellandserousuterinecarcinomawhatistherightadjuvanttherapy AT charlottebellier stageiclearcellandserousuterinecarcinomawhatistherightadjuvanttherapy AT florenceletinier stageiclearcellandserousuterinecarcinomawhatistherightadjuvanttherapy AT mariececileledeley stageiclearcellandserousuterinecarcinomawhatistherightadjuvanttherapy AT carlosmartinezgomez stageiclearcellandserousuterinecarcinomawhatistherightadjuvanttherapy AT ericleblanc stageiclearcellandserousuterinecarcinomawhatistherightadjuvanttherapy AT fabricenarducci stageiclearcellandserousuterinecarcinomawhatistherightadjuvanttherapy AT delphinehudry stageiclearcellandserousuterinecarcinomawhatistherightadjuvanttherapy |